DoH Policies screened during the period: 1st January 2017 to 31st March 2017
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- The Adoption and Children Bill
- Individual Funding Request (IFR) process
- NICE Clinical Guideline CG19 - Dental checks: intervals between oral health reviews
- NICE Clinical Guideline CG65 - Hypothermia: prevention and management in adults having surgery – Addendum
- NICE Public Health Guideline NG55 - Harmful sexual behaviour among children and young people
- NICE Clinical Guideline NG57 - Physical health of people in prison
- NICE Clinical Guideline NG59 - Low back pain and sciatica in over 16s: assessment and management (updates & replaces CG88)
- NICE Clinical Guideline NG61 - End of life care for infants, children and young people with life-limiting conditions: planning and management
- NICE Clinical Guideline NG62 - Cerebral palsy in under 25s: assessment and management
- NICE Technology Appraisal TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (review of TA295)
- NICE Technology Appraisal TA422 - Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (review of TA296)
- NICE Technology Appraisal TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (review of TA250)
- NICE Technology Appraisal TA424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
- NICE Technology Appraisal TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (review of TA241 & part review TA70)
- NICE Technology Appraisal TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (review of TA251 & part review of TA70)
- NICE Technology Appraisal TA427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
- NICE Technology Appraisal TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
- NICE Technology Appraisal TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
- NICE Technology Appraisal TA430 - Sofosbuvir-velpatasvir for treating chronic hepatitis C
- NICE Technology Appraisal TA431 - Mepolizumab for treating severe refractory eosinophilic asthma
- NICE Technology Appraisal TA432 - Everolimus for advanced renal cell carcinoma after previous treatment (review of TA219)
- NICE Technology Appraisal TA433 - Apremilast for treating active psoriatic arthritis (rapid review of TA372)
- Delivery plan arising from Programme for Government 2016-21 indicators 2,3,4 and 7
- PFG Indicator 5 - Improve the quality of the healthcare experience – Development of Quality Health and Social Care Experience Framework
- PFG Indicator 6 – Improve mental health
- PFG Indicator 10 - Improve support for Looked After Children